Shortage reports
Actual shortage:
257 (7%)
Anticipated shortage:
3 (0%)
Avoided shortage:
11 (0%)
Resolved:
3300 (92%)
3571
Discontinuation Reports
To be discontinued:
24 (7%)
Discontinued:
342 (93%)
Reversed:
0 (0%)
366
143 (4%)
32 (11%)
| Brand name | Strength | Dosage | Status | Date Created | Date Updated | Reports |
|---|---|---|---|---|---|---|
| APO-GABAPENTIN CAPSULES | 300MG | CAPSULE | Resolved | 2017-06-06 | 2017-08-16 | 12064 |
| APO-GABAPENTIN CAPSULES | 100MG | CAPSULE | Resolved | 2018-02-26 | 2018-04-24 | 41145 |
| APO-GABAPENTIN CAPSULES | 400MG | CAPSULE | Resolved | 2017-04-07 | 2017-09-15 | 5897 |
| APO-GABAPENTIN CAPSULES | 400MG | CAPSULE | Resolved | 2017-03-11 | 2017-03-29 | 604 |
| APO-GABAPENTIN CAPSULES | 300MG | CAPSULE | Resolved | 2017-03-11 | 2017-07-13 | 661 |
| APO-GABAPENTIN CAPSULES | 100MG | CAPSULE | Resolved | 2020-01-15 | 2020-02-10 | 103365 |
| APO-GAIN LIQ 20MG/ML | 20MG | LIQUID | Resolved | 2017-04-12 | 2018-02-26 | 6554 |
| APO-GATIFLOXACIN | 0.3% | SOLUTION | Resolved | 2023-09-28 | 2023-11-24 | 205486 |
| APO-GATIFLOXACIN | 0.3% | SOLUTION | Resolved | 2024-03-27 | 2024-04-12 | 223555 |
| APO-GATIFLOXACIN | 0.3% | SOLUTION | Actual shortage | 2025-08-14 | 2025-12-19 | 265272 |
| APO-GEFITINIB | 250MG | TABLET | Resolved | 2022-04-14 | 2022-06-24 | 158819 |
| APO-GEMFIBROZIL | 600MG | TABLET | Resolved | 2017-03-11 | 2019-11-26 | 610 |
| APO-GEMFIBROZIL CAP 300MG USP | 300 MG | CAPSULE | Resolved | 2017-03-11 | 2019-06-12 | 607 |
| APO-GLICLAZIDE | 80MG | TABLET | Resolved | 2022-01-28 | 2022-02-08 | 153780 |
| APO-GLICLAZIDE | 80MG | TABLET | Resolved | 2017-10-17 | 2018-05-22 | 26159 |
| APO-GLICLAZIDE | 80MG | TABLET | Resolved | 2023-04-21 | 2023-06-29 | 189988 |
| APO-GLICLAZIDE | 80MG | TABLET | Resolved | 2024-04-19 | 2024-06-07 | 225799 |
| APO-GLICLAZIDE | 80MG | TABLET | Resolved | 2024-04-05 | 2024-06-07 | 224583 |
| APO-GLICLAZIDE | 80MG | TABLET | Resolved | 2025-10-03 | 2025-10-10 | 268555 |
| APO-GLICLAZIDE | 80MG | TABLET | Resolved | 2024-06-20 | 2024-08-02 | 231033 |
| Brand name | Strength | Dosage | Status | Date Created | Date Updated | Reports |
|---|---|---|---|---|---|---|
| APO-HYDROMORPHONE CR | 12MG | CAPSULE (EXTENDED RELEASE) | Discontinued | 2020-04-04 | 2020-04-04 | 110962 |
| APO-HYDROMORPHONE CR | 18MG | CAPSULE (EXTENDED RELEASE) | Discontinued | 2020-04-04 | 2020-04-04 | 110965 |
| APO-HYDROMORPHONE CR | 24MG | CAPSULE (EXTENDED RELEASE) | Discontinued | 2020-04-04 | 2020-04-04 | 110968 |
| APO-HYDROMORPHONE CR | 30MG | CAPSULE (EXTENDED RELEASE) | Discontinued | 2020-04-04 | 2020-04-04 | 110971 |
| APO-HYDROMORPHONE CR | 4.5MG | CAPSULE (EXTENDED RELEASE) | Discontinued | 2020-04-04 | 2020-04-04 | 110974 |
| APO-HYDROMORPHONE CR | 3MG | CAPSULE (EXTENDED RELEASE) | Discontinued | 2020-04-04 | 2020-04-04 | 110956 |
| APO-HYDROXYQUINE | 200MG | TABLET | Discontinued | 2018-09-07 | 2018-10-05 | 60524 |
| APO-IMIQUIMOD | Discontinued | 2019-11-26 | 2019-11-26 | 99672 | ||
| APO-IRBESARTAN | 150MG | TABLET | Discontinued | 2018-09-07 | 2018-12-28 | 60536 |
| APO-IRBESARTAN | 300MG | TABLET | Discontinued | 2019-01-04 | 2019-01-04 | 71237 |
| APO-IRBESARTAN | 75MG | TABLET | Discontinued | 2019-01-04 | 2019-01-04 | 71231 |
| APO-IRBESARTAN | 300MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60539 |
| APO-IRBESARTAN | 150MG | TABLET | Discontinued | 2019-01-04 | 2019-01-04 | 71234 |
| APO-IRBESARTAN/HCTZ | 25MG 300MG | TABLET | Discontinued | 2018-02-23 | 2018-09-15 | 40769 |
| APO-IRBESARTAN/HCTZ | 12.5MG 150MG | TABLET | Discontinued | 2018-02-23 | 2018-07-17 | 40760 |
| APO-IRBESARTAN/HCTZ | Discontinued | 2018-09-07 | 2018-09-15 | 60548 | ||
| APO-IRBESARTAN/HCTZ | 25MG 300MG | TABLET | Discontinued | 2018-02-23 | 2018-09-15 | 40766 |
| APO-IRBESARTAN/HCTZ | Discontinued | 2018-02-23 | 2018-07-17 | 40763 | ||
| APO-IRBESARTAN/HCTZ | 12.5MG 150MG | TABLET | Discontinued | 2018-02-23 | 2018-02-23 | 40757 |
| APO-LAMIVUDINE | 150MG | TABLET | Discontinued | 2018-09-07 | 2019-07-13 | 60557 |